AIMS: Intravenous high-dose free methylprednisolone (MP) hemisuccinate is the primary treatment for an acute relapse in relapsing-remitting multiple sclerosis. However, it is inconvenient and its side effects are undesirable. Both dose and dosing frequency can be reduced by incorporating free MP in glutathione-PEGylated liposomes, creating a slow-release formulation with reduced toxicity and prolonged peripheral efficacy. This first-in-human study was designed to assess the safety, pharmacokinetics and pharmacodynamics of glutathione-PEGylated liposomes containing MP (2B3-201). METHODS: The first part was a double-blind, three-way cross over study in 18 healthy male subjects, receiving ascending doses of 2B3-201, active comparator (free MP) orplacebo. Part 2 of the study was an open-label infusion of 2B3-201 (different doses), exploring pretreatment with antihistamines and different infusion schedules in another 18 healthy male subjects, and a cross-over study in six healthy female subjects. MP plasma concentrations, lymphocyte counts, adrenocorticotropic hormone, osteocalcin and fasting glucose were determined. Safety and tolerability profiles were assessed based on adverse events, safety measurements and central nervous system tests. RESULTS: The most frequent recorded AE related to 2B3-201 was an infusion related reaction (89%). 2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose. CONCLUSION: 2B3-201 is considered safe, with no clinically relevant changes in central nervous system safety parameters and no serious adverse events. In addition, 2B3-201 shows a long plasma half-life and prolonged immunosuppressive effects.
RCT Entities:
AIMS: Intravenous high-dose free methylprednisolone (MP) hemisuccinate is the primary treatment for an acute relapse in relapsing-remitting multiple sclerosis. However, it is inconvenient and its side effects are undesirable. Both dose and dosing frequency can be reduced by incorporating free MP in glutathione-PEGylated liposomes, creating a slow-release formulation with reduced toxicity and prolonged peripheral efficacy. This first-in-human study was designed to assess the safety, pharmacokinetics and pharmacodynamics of glutathione-PEGylated liposomes containing MP (2B3-201). METHODS: The first part was a double-blind, three-way cross over study in 18 healthy male subjects, receiving ascending doses of 2B3-201, active comparator (free MP) or placebo. Part 2 of the study was an open-label infusion of 2B3-201 (different doses), exploring pretreatment with antihistamines and different infusion schedules in another 18 healthy male subjects, and a cross-over study in six healthy female subjects. MP plasma concentrations, lymphocyte counts, adrenocorticotropic hormone, osteocalcin and fasting glucose were determined. Safety and tolerability profiles were assessed based on adverse events, safety measurements and central nervous system tests. RESULTS: The most frequent recorded AE related to 2B3-201 was an infusion related reaction (89%). 2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose. CONCLUSION: 2B3-201 is considered safe, with no clinically relevant changes in central nervous system safety parameters and no serious adverse events. In addition, 2B3-201 shows a long plasma half-life and prolonged immunosuppressive effects.
Authors: F Sellebjerg; D Barnes; G Filippini; R Midgard; X Montalban; P Rieckmann; K Selmaj; L H Visser; P S Sørensen Journal: Eur J Neurol Date: 2005-12 Impact factor: 6.089
Authors: Georgina M Russell; David E Henley; Jack Leendertz; Jennie A Douthwaite; Susan A Wood; Adam Stevens; Wolfram W Woltersdorf; Bernard W M M Peeters; Ge S F Ruigt; Anne White; Johannes D Veldhuis; Stafford L Lightman Journal: J Neurosci Date: 2010-04-28 Impact factor: 6.167
Authors: S L de Haas; S J de Visser; J P van der Post; M de Smet; R C Schoemaker; B Rijnbeek; A F Cohen; J M Vega; N G B Agrawal; T V Goel; R C Simpson; L K Pearson; S Li; M Hesney; M G Murphy; J M A van Gerven Journal: J Psychopharmacol Date: 2006-11-08 Impact factor: 4.153
Authors: Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker Journal: Ann Emerg Med Date: 2006-04 Impact factor: 5.721
Authors: Peter Joseph Jongen; Ioanna Stavrakaki; Bernard Voet; Erwin Hoogervorst; Erik van Munster; Wim H Linssen; Ludovicus G Sinnige; Wim I Verhagen; Leo H Visser; Ruud van der Kruijk; Freek Verheul; Jan Boringa; Marco Heerings; Werner Gladdines; Fredrik Lönnqvist; Pieter Gaillard Journal: J Neurol Date: 2016-06-07 Impact factor: 4.849
Authors: Sybille D Reichardt; Agathe Amouret; Chiara Muzzi; Sabine Vettorazzi; Jan P Tuckermann; Fred Lühder; Holger M Reichardt Journal: Cells Date: 2021-10-28 Impact factor: 6.600